Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Beers

Showing results (91-100 of 104) with videos related to

Pageof 11
Sort By:
Blood|March 13, 2010
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selectionStephen A Beers, Ruth R French, H T Claude Chan, et al.
Cell Reports|July 20, 2022
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanismsAlexander P Simpson, Ali Roghanian, Robert J Oldham, et al.
Blood|July 20, 2011
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacySean H Lim, Andrew T Vaughan, Margaret Ashton-Key, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 16, 2014
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerizationAnn L White, Lang Dou, H T Claude Chan, et al.
Cancer Immunology Research|September 26, 2025
A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for ImmunotherapyKirstie L S Cleary, Monika Semmrich, Linda Martensson, et al.
Cancer Cell|December 16, 2014
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodiesAnn L White, H T Claude Chan, Ruth R French, et al.
Cancer Research|November 10, 2022
ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy ResistanceMassimiliano Mellone, Klaudia Piotrowska, Giulia Venturi, et al.
Cancer Cell|December 5, 2017
Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid RecruitmentAnna H Turaj, Khiyam Hussain, Kerry L Cox, et al.
Immunity|April 16, 2017
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established TumorsFrederick Arce Vargas, Andrew J S Furness, Isabelle Solomon, et al.
Blood Advances|July 29, 2021
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatmentMalgorzata Nowicka, Laura K Hilton, Margaret Ashton-Key, et al.
Pageof 11

Showing results (91-100 of 104) with videos related to

Sort By:
Pageof 11
Blood|March 13, 2010
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selectionStephen A Beers, Ruth R French, H T Claude Chan, et al.
Cell Reports|July 20, 2022
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanismsAlexander P Simpson, Ali Roghanian, Robert J Oldham, et al.
Blood|July 20, 2011
Fc gamma receptor IIb on target B cells promotes rituximab internalization and reduces clinical efficacySean H Lim, Andrew T Vaughan, Margaret Ashton-Key, et al.
Journal of Immunology (Baltimore, Md. : 1950)|July 16, 2014
Fcγ receptor dependency of agonistic CD40 antibody in lymphoma therapy can be overcome through antibody multimerizationAnn L White, Lang Dou, H T Claude Chan, et al.
Cancer Immunology Research|September 26, 2025
A "Function-First" Approach to Identify Regulatory T cell-Targeting Antibodies for ImmunotherapyKirstie L S Cleary, Monika Semmrich, Linda Martensson, et al.
Cancer Cell|December 16, 2014
Conformation of the human immunoglobulin G2 hinge imparts superagonistic properties to immunostimulatory anticancer antibodiesAnn L White, H T Claude Chan, Ruth R French, et al.
Cancer Research|November 10, 2022
ATM Regulates Differentiation of Myofibroblastic Cancer-Associated Fibroblasts and Can Be Targeted to Overcome Immunotherapy ResistanceMassimiliano Mellone, Klaudia Piotrowska, Giulia Venturi, et al.
Cancer Cell|December 5, 2017
Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid RecruitmentAnna H Turaj, Khiyam Hussain, Kerry L Cox, et al.
Immunity|April 16, 2017
Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established TumorsFrederick Arce Vargas, Andrew J S Furness, Isabelle Solomon, et al.
Blood Advances|July 29, 2021
Prognostic significance of FCGR2B expression for the response of DLBCL patients to rituximab or obinutuzumab treatmentMalgorzata Nowicka, Laura K Hilton, Margaret Ashton-Key, et al.
Pageof 11